Chemotherapy Regimen for High-Grade Neuroendocrine Carcinoma of the Larynx
For high-grade neuroendocrine carcinoma of the larynx, treat with platinum-etoposide chemotherapy following small cell lung cancer protocols, specifically cisplatin 100 mg/m² or carboplatin AUC 6 plus etoposide, as these tumors behave like small cell carcinomas regardless of anatomic site. 1
Treatment Algorithm Based on Tumor Grade
High-Grade (Poorly Differentiated) or Small Cell Subtype
The NCCN guidelines explicitly state that poorly differentiated (high-grade or anaplastic) or small cell neuroendocrine tumors should follow NCCN Guidelines for Small Cell Lung Cancer 1. This recommendation is based on the biological behavior of these tumors, which are chemosensitive and aggressive regardless of primary site.
Preferred regimen options:
- Cisplatin 100 mg/m² IV day 1 + Etoposide (every 3 weeks) 1
- Carboplatin AUC 6 + Etoposide (equally effective, particularly for elderly or poor-risk patients) 1
The carboplatin-etoposide combination showed equivalent efficacy to cisplatin-etoposide in the JCOG 9702 trial, with response rates of 73% for both regimens and median overall survival of 10.6 months versus 9.9 months 1.
Alternative Regimen for Selected Cases
Paclitaxel + Carboplatin + Etoposide is an alternative that showed promising results in poorly differentiated neuroendocrine carcinomas, with 53% major response rate and median survival of 14.5 months 1. This triple-drug regimen demonstrated 2-year and 3-year survival rates of 33% and 24% respectively 1.
Critical Clinical Context
Why This Matters
High-grade neuroendocrine carcinoma of the larynx is exceptionally rare (accounting for <0.5% of laryngeal carcinomas) but extraordinarily aggressive 2. These tumors present with:
- Cervical lymph node metastases in approximately 50% of cases at diagnosis 2
- High propensity for distant metastasis (57.7% of failures occur at distant sites) 3
- Historical 2-year and 5-year survival rates of only 16% and 5% respectively with inadequate treatment 2
Multimodality Approach
Chemotherapy alone is insufficient. The evidence strongly supports:
- Neoadjuvant chemotherapy followed by surgery and adjuvant chemoradiotherapy for advanced disease 3
- Concurrent chemoradiotherapy as definitive treatment when surgery is not feasible
- Elective nodal irradiation (ENI) significantly improves regional control (100% vs 68.6% at 5 years) 3
Response Assessment is Prognostic
Major pathological response (≤10% residual tumor) after neoadjuvant chemotherapy predicts significantly better 5-year overall survival (85.7% vs 18.5%) 3. This makes response-adapted treatment strategies particularly important.
Common Pitfalls to Avoid
Do not treat like squamous cell carcinoma of the larynx: These tumors require platinum-etoposide, not the cisplatin-5FU or taxane-based regimens used for squamous cell carcinoma 4
Do not use carcinoid tumor protocols: Well-differentiated neuroendocrine tumors follow different guidelines; high-grade tumors require aggressive small cell lung cancer protocols 1
Do not omit systemic therapy: Combined radiation and chemotherapy offer the best survival; radiation or surgery alone results in poor outcomes 2
Prophylactic cranial irradiation (PCI) appears unnecessary: Unlike small cell lung cancer, brain metastases are rare (4.2% in one series), and PCI can be safely omitted 3
Prognostic Factors to Consider
Poor prognostic indicators include:
- Age <50 years 3
- Laryngeal primary site (compared to sinonasal) 3, 5
- Advanced local stage (T3-T4) 3
- Nodal metastasis 3
- Lack of major pathological response to neoadjuvant chemotherapy 3
Laryngeal neuroendocrine carcinoma specifically shows worse 5-year distant metastasis-free survival (41.2% vs 87.5%) and overall survival (38.1% vs 92.9%) compared to other head and neck sites 5.